| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-13075SS | |||
| Azide and BSA Free | NBP2-80594 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-92693SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-506SS | |||
| Azide and BSA Free | NBP2-80571 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-268SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-1612-0.05ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-05198-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77686SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-37235SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-556-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22112SS | |||
| Azide and BSA Free | NBP2-80821 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-1639SS | |||
| Azide and BSA Free | NBP2-80569 | |||
![Immunocytochemistry/ Immunofluorescence: beta Amyloid Antibody (MOAB-2) - BSA Free [NBP2-13075] - No difference in A beta plaque load between propofol (n = 8) & vehicle (n = 6) treated APP/PS1 mice. a An example image of A beta plaque immunoreactivity in the cortex of an APP/PS1 mouse following repeated propofol exposure. b A representative image of A beta plaque immunolabeling the cortex of an APP/PS1 mouse following treatment with vehicle. c Bar graph showing the percentage of the cortex occupied by A beta plaques in propofol & vehicle treated APP/PS1 mice. d Bar graph showing the average size (μm2) of A beta plaques in the cortex of APP/PS1 in the propofol & vehicle treatment groups. e Bar graph showing the average density of A beta plaques (/μm2) in the cortex of propofol & vehicle exposed APP/PS1 mice. All data is shown as mean ± SEM. Scale bar = 500 μm Image collected & cropped by CiteAb from the following publication (//bmcanesthesiol.biomedcentral.com/articles/10.1186/s12871-018-0509-5), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-13075_mouse-monoclonal-beta-amyloid-antibody-moab-2-310202416114798.jpg)
![Analysis of whole brain tissue lysates using mouse mAb to FOX3/NeuN NBP1-92693, dilution 1:1,000 in green: [1] protein standard (red), [2] adult rat brain, [3] embryonic E20 rat brain, [4] adult mouse brain. Note the strong twin bands corresponding to the two alternate transcripts of FOX3/NeuN protein with apparent SDS-PAGE molecular weights of 46 and 48kDa. As with other FOX3/NeuN antibodies, an additional band at ~70kDa is revealed in some lysates.](http://images.novusbio.com/fullsize/RBFOX3-NeuN-Antibody-1B7-Western-Blot-NBP1-92693-img0020.jpg)
![Immunocytochemistry/ Immunofluorescence: RBFOX3/NeuN Antibody (1B7) [NBP1-92693] - NF kappa B localizes to both neuronal & glial nuclei in superior colliculus. Representative confocal images of NF kappa B in the superior colliculus (SC) of vehicle- & HE3286-treated rats with all nuclei indicated (DAPI). Sections were also labeled for astrocytes (A, GFAP), microglia (B, Iba1), or neurons using antibodies against either NeuN (C) or phosphorylated neurofilament heavy (pNFH; D). Representative nuclei from each cell class demonstrated NF kappa B localization (arrows). Insets (solid white, B) show region contained within dashed box with red channel removed to better visualize nuclear localization of NF kappa B. Scale: 10 μm. Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fnins.2017.00045/full), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-92693_mouse-monoclonal-rbfox3-neun-antibody-1b7-310202415382419.jpg)
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YL1/2) [NB600-506] - HeLa cells were fixed and permeabilized for 10 minutes with -20C MeOH. The cells were incubated with alpha Tubulin Antibody [YL1/2] (NB600-506) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Immunocytochemistry-Immunofluorescence-NB600-506-img0021.jpg "Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YL1/2) [NB600-506] - HeLa cells were fixed and permeabilized for 10 minutes with -20C MeOH. The cells were incubated with alpha Tubulin Antibody [YL1/2] (NB600-506) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Flow Cytometry: alpha Tubulin Antibody (YL1/2) [NB600-506] - An intracellular stain was performed on SH-SY5Y cells with alpha Tubulin (YL1/2) Antibody NB600-506G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Flow-Cytometry-NB600-506-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YL1/2) [NB600-506] - NIH3T3 cells were fixed and permeabilized for 10 minutes with -20C MeOH. The cells were incubated with alpha Tubulin Antibody [YL1/2] (NB600-506) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-NB600-506-img0022.jpg)
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YL1/2) [NB600-506] - Rat FR cells were fixed and permeabilized for 10 minutes with -20C MeOH. The cells were incubated with alpha Tubulin Antibody [YL1/2] (NB600-506) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Immunocytochemistry-Immunofluorescence-NB600-506-img0023.jpg)
![Western Blot: alpha Tubulin Antibody (YL1/2) [NB600-506] - Total protein from human HeLa, mouse 3T3, rat PC12 and African green monkey Cos7 cell lines was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with a 1:6000 dilution of anti-Tubulin (YL 1/2) in 1% non-fat milk in TBST and detected with an anti-rat HRP secondary antibody using chemiluminescence. Alpha tubulin molecular weight: 50 kDa.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Western-Blot-NB600-506-img0015.jpg)
![Immunohistochemistry-Paraffin: alpha Tubulin Antibody (YL1/2) [NB600-506] - Tubulin antibody was tested in human breast cancer xenograft using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Immunohistochemistry-Paraffin-NB600-506-img0005.jpg)
![Flow Cytometry: alpha Tubulin Antibody (YL1/2) [NB600-506] - An intracellular stain was performed on PC12 cells with Tubulin [YL1/2] Antibody NB600-506AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Flow-Cytometry-NB600-506-img0017.jpg)
![Western Blot: alpha Tubulin Antibody (YL1/2) [NB600-506] - Tissue levels of VEGF and PCNA.VEGF levels were estimated by western blot. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0112995), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Western-Blot-NB600-506-img0019.jpg)
![Western Blot: alpha Tubulin Antibody (YL1/2) [NB600-506] - Western blot analysis of alpha Tubulin (molecular weight: 50 kDa) expression in 1) HeLa, 2) NTERA-2, 3) A431, 4) HepG2, 5) MCF7, 6) NIH-3T3, 7) PC-12 and 8) Cos 7 whole cell lysates using NB600-506.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Western-Blot-NB600-506-img0002.jpg)
![Western Blot: alpha Tubulin Antibody (YL1/2) [NB600-506] - Western Blot analysis of whole cell lysates of HeLa, NIH-3T3 and PC-12 cell lines using Tubulin antibody (clone YL1/2). Alpha tubulin molecular weight: 50 kDa.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Western-Blot-NB600-506-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YL1/2) [NB600-506] - Tubulin YL1/2 antibody was tested in HeLa cells with Dylight 550 (red). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Immunocytochemistry-Immunofluorescence-NB600-506-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YL1/2) [NB600-506] - B-Tubulin staining (488) and Pericentrin (594) in Mitotic Cell. Image from verified customer review.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Immunocytochemistry-Immunofluorescence-NB600-506-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YL1/2) [NB600-506] - IF Confocal analysis of NIH/3T3 cells using Tubulin antibody (NB600-506, 1:5). An Alexa Fluor 488-conjugated Goat to rat IgG was used as secondary antibody (green). Actin filaments were labeled with Alexa Fluor 568 phalloidin (red). DAPI was used to stain the cell nuclei (blue).](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Immunocytochemistry-Immunofluorescence-NB600-506-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YL1/2) [NB600-506] - HeLa cells were fixed and permeabilized for 10 minutes using -20C MeOH. The cells were incubated with anti-Tubulin (YL1/2) at a 1:200 dilution overnight at 4C and detected with an anti-rat Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Immunocytochemistry-Immunofluorescence-NB600-506-img0013.jpg)
![Flow Cytometry: alpha Tubulin Antibody (YL1/2) [NB600-506] - Analysis of Alexa Fluor (R) 647 conjugate of NB600-506. An intracellular stain was performed on HeLa cells with Tubulin antibody (YL1/2) NB600-506AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Flow-Cytometry-NB600-506-img0012.jpg)
![Flow Cytometry: alpha Tubulin Antibody (YL1/2) [NB600-506] - An intracellular stain was performed on NIH3T3 cells with Tubulin [YL1/2] Antibody NB600-506AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YL1-2-Flow-Cytometry-NB600-506-img0016.jpg)
![Western Blot: alpha Tubulin Antibody (YL1/2) - BSA Free [NB600-506] - Tissue levels of VEGF & PCNA.VEGF levels were estimated by (A) western blot & (B) ELISA. (C) PCNA levels estimated by western blot. Data were normalized with tubulin. (D) Representative images of PCNA immunohistochemistry staining in the nucleus is shown for CS-exposed mice (CSE) & CS-exposed & LGF-treated mice (CSE+LGF). Scale bars = 50 µm. LGF promoted an increase of PCNA+ cells as showed in the bar graph. ** P<0.01 vs. air-exposed mice; ¥ P<0.05 vs. CS-exposed mice (n = 5 per group). Data are presented as mean ± SEM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25401951), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-506_rat-monoclonal-alpha-tubulin-antibody-yl1-2-310202415304283.jpg)
![Western Blot: alpha Tubulin Antibody (YL1/2) - BSA Free [NB600-506] - LGF ameliorates oxidative stress.Bars represent (A) 3NT & (B) Nrf2 levels estimated by western blot. Data were normalized with tubulin. * P<0.05 vs. air-exposed mice; ¥ P<0.05 vs. CS-exposed mice (n = 5 per group). Data are presented as mean ± SEM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25401951), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-506_rat-monoclonal-alpha-tubulin-antibody-yl1-2-31020241539740.jpg)
![Western Blot: alpha Tubulin Antibody (YL1/2) - BSA Free [NB600-506] - Tissue levels of VEGF & PCNA.VEGF levels were estimated by (A) western blot & (B) ELISA. (C) PCNA levels estimated by western blot. Data were normalized with tubulin. (D) Representative images of PCNA immunohistochemistry staining in the nucleus is shown for CS-exposed mice (CSE) & CS-exposed & LGF-treated mice (CSE+LGF). Scale bars = 50 µm. LGF promoted an increase of PCNA+ cells as showed in the bar graph. ** P<0.01 vs. air-exposed mice; ¥ P<0.05 vs. CS-exposed mice (n = 5 per group). Data are presented as mean ± SEM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25401951), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-506_rat-monoclonal-alpha-tubulin-antibody-yl1-2-31020241534356.jpg)
![Western Blot: alpha Tubulin Antibody (YL1/2) - BSA Free [NB600-506] - LGF ameliorates oxidative stress.Bars represent (A) 3NT & (B) Nrf2 levels estimated by western blot. Data were normalized with tubulin. * P<0.05 vs. air-exposed mice; ¥ P<0.05 vs. CS-exposed mice (n = 5 per group). Data are presented as mean ± SEM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25401951), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-506_rat-monoclonal-alpha-tubulin-antibody-yl1-2-310202415284516.jpg)
![Western Blot: alpha Tubulin Antibody (YL1/2) - BSA Free [NB600-506] - Role of cell-type-specific cyclooxygenase-2 (Cox-2) expression in Ras/p53-mediated tumor formation. a Experimental scheme. b Microscopic phenotype & histology of three-dimensional (3D) organoids with/without celecoxib treatment. c Relative 3D organoid formation was determined by the number of organoids larger than 100 µm, n = 3 independent experiments, 25 fields at high power field (HPF) per sample. Veh, vehicle control; C25, 25 µM; C50, 50 µM celecoxib. d Experimental scheme. e Ras/p53-mediated tumor incidence with/without condition Cox-2 knockout. Ptgs2wt/wt, n = 15 animals; Ptgs2flox/flox, n = 14 animals. f, g Histological phenotypes. h–k Immunoblotting of Keratin5 (Krt5), Krt6 & Loricrin (Lor) demonstrated decreased tumor susceptibility but increased differentiation status, n = 4 independent experiments. l Summary of the contribution of physiological stress factors in the susceptibility of tumor development from tumor-competent Krt15+ progenitors. Data with bar graphs are represented as mean ± SEM. Statistical significance was determined by pair-wise comparison using t test; ns = not significant, *p < 0.05, **p < 0.005. Scale bars, 100 µm. Ptgs2 prostaglandin-endoperoxide synthase 2 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31110179), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-506_rat-monoclonal-alpha-tubulin-antibody-yl1-2-31020241616019.jpg)
![Western Blot: alpha Tubulin Antibody (YL1/2) - BSA Free [NB600-506] - Microenvironmental acidic stressors & tumor susceptibility. a Experimental scheme. Epithelial cells isolated from the regions adjacent or distant from squamocolumnar junction (SCJ). b Microscopic phenotype of three-dimensional (3D) organoids from control & Krt15-CrePR; LSL-KrasG12D; p53flox/flox mice. Histology of 3D organoids demonstrated that oncogenic Ras/p53 increased abnormal growth features. c–e Quantification of relative organoid formation (n = 3 independent experiments, 25 fields at high power field (HPF) per sample) & size distribution (n ≥ 150) from control & experimental mice expressing oncogenic Ras/p53 combination. f Experimental scheme. Phosphate-buffered saline (PBS) (vehicle) or PPI were daily treated by intraperitoneal (i.p.) injections (5 consecutive days per week). g Tumor incidence from Krt15-CrePR; LSL-KrasG12D; p53flox/flox mice, with/without PPI treatment, n = 9 animals per each. Statistical significance was determined by Fisher’s exact test; *p < 0.05. h–j Immunoblotting of Keratin5 (Krt5) & Krt6 demonstrated relatively less tumor formation in the PPI treatment group, n = 5 independent experiments. k–m Immunostaining of Krt5, Krt6, & phospho-histone H3 (ph-H3), & histology demonstrated suppressed tumor formation by daily PPI treatment in Krt15-CrePR; LSL-KrasG12D; p53flox/flox mice. PPI, proton pump inhibitor. Data with bar graphs are represented as mean ± SEM. Statistical significance was determined by pair-wise comparison using t test; *p < 0.05, **p < 0.005. Scale bars, 100 µm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31110179), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-506_rat-monoclonal-alpha-tubulin-antibody-yl1-2-31020241618944.jpg)
![Western Blot: LRRK2 Antibody [NB300-268] - Western blotting of LRRK2. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T and M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, and Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Western-Blot-NB300-268-img0023.jpg "<b>Independent Antibodies Validation. </b>Western Blot: LRRK2 Antibody [NB300-268] - Western blotting of LRRK2. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T and M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, and Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.")
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Frozen: LRRK2 Antibody [NB300-268] - Staining as described in PMID 24312256. Image from verified customer review.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Frozen-NB300-268-img0014.jpg)
![Western Blot: LRRK2 Antibody [NB300-268] - LRRK2 N-terminal sequences show increased aggregation. Western blots of cell lysates of SH-SY5Y cells transfected with indicated LRRK2 construct showed equal expression of the LRRK2 protein with anti-HA (top panel) or anti-C-terminal- (bottom panel) LRRK2 antibody. Equal lysate loading is indicated by Beta-actin loading control. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0045149) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Western-Blot-NB300-268-img0028.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - Specificity of immunostaining for LRRK2. Specificity of the antibodies used for immunocytochemistry was determined by performing adsorptions with the corresponding peptide sequences. Immunochemical localization of LBs (arrows) by Ab1 against LRRK2900-100 (left) was blocked using respective peptide antigens (right). Adjacent sections with LB within pigmented neurons from the substantia nigra of a case of PD were used. Scale bar: 20 um. Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0026.jpg)
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - Immunocytochemistry of LRRK2 in PD using antibodies (Ab1, Ab4) raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD. Scale bars: 10 um (top); E-L = 100 um (bottom). Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0025.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - Analysis using the Alexa Fluor 647 conjugate of NB300-268. Staining of LRRK2 in normal human peripheral blood cells (anticoagulated Lithium-Heparin) using anti-LRRK2 antibody conjugated with AF647. The primary antibody was used at a dilution of 1:200 and incubated for 20 min at room temperature. Image from verified customer review.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0019.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - LRRK2 accumulates in globules in alphaS tg mice. Triple immunofluorescence for alphaS, LRRK2 and Rab5B for basal ganglia in alphaS tg mice. LRRK2 and Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alphaS-globule (arrowhead) Scale bar = 10 um for all panels. Image collected and cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0024.jpg)
![Immunocytochemistry/Immunofluorescence: LRRK2 Antibody [NB300-268] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-LRRK2 Antibody NB300-268 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunocytochemistry-Immunofluorescence-NB300-268-img0031.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - An intracellular stain was performed on U2OS cells with LRRK2 Antibody NB300-268 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0030.jpg)
![Immunocytochemistry/Immunofluorescence: LRRK2 Antibody [NB300-268] - LRRK2 antibody was tested in SH-SY-5Y cells at a 1:200 dilution against DyLight 488 (Green). Alpha tubulin and nuclei were counterstained against DyLight 568 (Red), and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunocytochemistry-Immunofluorescence-NB300-268-img0015.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - Staining of human brain, Putamen, Neurons and Glia using a 60X magnification.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0020.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - An intracellular stain was performed on U2OS cells with LRRK Antibody NB300-268AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0022.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - An intracellular stain was performed on Neuro2a cells with LRRK2 Antibody NB300-268 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0029.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Western blotting of LRRK2. A. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T & M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, & Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). B. Recombinant LRRK2 (arrowhead) from transfected M17 cells is detected by anti-LRRK2 Ab4 (lane 1), but not after absorption of the antibody with its peptide antigen (lane 2). Brain LRRK2 was recognized by anti-LRRK2 Ab4 in two controls (lanes 3 & 4) & two PD cases (lanes 5 & 6). Cell lysates (10 μg protein) & brain homogenates (100 μg protein) were prepared & loaded on 6% SDS-PAGE gels for Western blot analysis using anti-LRRK2 antibodies Ab1–Ab4 in (A) & Ab4 in (B). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415371926.jpg)
![Flow Cytometry: LRRK2 Antibody - BSA Free [NB300-268] - Deletion of LRRK2 attenuates Mn-induced apoptosis & cell death in RAW 264.7 cells.(A) LRRK2 WT or KO RAW 264.7 cells were treated with Mn (250 μM) for the designated times, followed by flow cytometry analysis to determine Mn-induced apoptosis. Both early & late apoptotic cells (Q2 & Q3) were measured. (B) At the end of Mn exposure, cell viability was determined by MTT assay. @@@, p < 0.001; ###, p < 0.001; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3, for apoptosis assay; n = 6, for MTT assay). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241539739.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 accumulates in globules in alpha S tg mice. (a & b) Double immunofluorescence for alpha S with parkin, PINK1, DJ-1, LRRK2, or negative control (the immunopeptide-preabsorbed anti-LRRK2 antibody) in alpha S tg mice (a) & P123H beta S tg mice (b). Note that alpha S-globules were immunopositive for LRRK2 (~79%, n = 22), whereas P123H beta S globules were negative for LRRK2. Representative images are shown for the thalamus ( alpha S) & basal ganglia (P123H beta S). Scale bar = 5 μm for all panels. (c) Triple immunofluorescence for alpha S, LRRK2 & Rab5B for basal ganglia in alpha S tg mice. LRRK2 & Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alpha S-globule (arrowhead) Scale bar = 10 μm for all panels. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241538242.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Specificity of immunostaining for LRRK2. Specificity of the antibodies used for immunocytochemistry was determined by performing adsorptions with the corresponding peptide sequences. Immunochemical localization of LBs (arrows) by Ab4 against LRRK22500–2527 (A) & Ab1 against LRRK2900–100 (C) was blocked using respective peptide antigens (B & D). Adjacent sections with LB within pigmented neurons from the substantia nigra of a case of PD were used. Scale bar: 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415392599.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415304221.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241534387.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 accumulates in globules in alpha S tg mice. (a & b) Double immunofluorescence for alpha S with parkin, PINK1, DJ-1, LRRK2, or negative control (the immunopeptide-preabsorbed anti-LRRK2 antibody) in alpha S tg mice (a) & P123H beta S tg mice (b). Note that alpha S-globules were immunopositive for LRRK2 (~79%, n = 22), whereas P123H beta S globules were negative for LRRK2. Representative images are shown for the thalamus ( alpha S) & basal ganglia (P123H beta S). Scale bar = 5 μm for all panels. (c) Triple immunofluorescence for alpha S, LRRK2 & Rab5B for basal ganglia in alpha S tg mice. LRRK2 & Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alpha S-globule (arrowhead) Scale bar = 10 μm for all panels. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241517133.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 accumulates in globules in alpha S tg mice. (a & b) Double immunofluorescence for alpha S with parkin, PINK1, DJ-1, LRRK2, or negative control (the immunopeptide-preabsorbed anti-LRRK2 antibody) in alpha S tg mice (a) & P123H beta S tg mice (b). Note that alpha S-globules were immunopositive for LRRK2 (~79%, n = 22), whereas P123H beta S globules were negative for LRRK2. Representative images are shown for the thalamus ( alpha S) & basal ganglia (P123H beta S). Scale bar = 5 μm for all panels. (c) Triple immunofluorescence for alpha S, LRRK2 & Rab5B for basal ganglia in alpha S tg mice. LRRK2 & Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alpha S-globule (arrowhead) Scale bar = 10 μm for all panels. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415304292.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Western blotting of LRRK2. A. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T & M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, & Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). B. Recombinant LRRK2 (arrowhead) from transfected M17 cells is detected by anti-LRRK2 Ab4 (lane 1), but not after absorption of the antibody with its peptide antigen (lane 2). Brain LRRK2 was recognized by anti-LRRK2 Ab4 in two controls (lanes 3 & 4) & two PD cases (lanes 5 & 6). Cell lysates (10 μg protein) & brain homogenates (100 μg protein) were prepared & loaded on 6% SDS-PAGE gels for Western blot analysis using anti-LRRK2 antibodies Ab1–Ab4 in (A) & Ab4 in (B). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241536376.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415175254.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415345320.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415384173.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 deletion attenuates Mn-induced pro-apoptotic protein levels.(A) After cells (LRRK2 WT & LRRK2 KO) were exposed to Mn (250 μM) for up to 24 h, total protein was extracted & followed by western blot analysis to determine protein levels of Bax & Daxx. beta -actin was used as a loading control. (B) The expression levels of Bax & Daxx modulated by Mn were quantified relative to its control levels in LRRK2 WT & KO cells. **, p < 0.01; ***, p < 0.001 (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241535611.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - The interaction & phosphorylation of LRRK2 & LC1. (A) Cellular co-localisation of endogenous LRRK2 & MAP1B (LC1). SKNSH cells were labelled with LRRK2 (green) & LC1 (red) antibodies & signals were detected by immunofluorescence. Detailed figure in Additional file 1. (B) LRRK2 kinase assay. The LRRK2 wild-typed (WT) kinase interacted & phosphorylated the LC1 domain unlike the LRRK2 kinase-dead protein. (C) Western blotting of LRRK2 & LC1 proteins after a kinase assay. Both LRRK2 & LC1 proteins were probed for phospho-threonine & phospho-serine signals respectively. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-7-29), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415382414.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621814.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in PD. Four antibodies raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD (A-H) & age-matched controls (I-L). Intense immunolabeling of brainstem LBs in cases of PD was seen with Ab1 against LRRK2900–100 (A) & Ab4 against LRRK22500–2527(D). Both rim (A & D) & core (inset in D) of LBs were recognized. In contrast, LBs were not labelled in any case using antibodies directed against LRRK21246–1265 (Ab2, B) or LRRK21838–2133 (Ab3, C), for which the antigenic sites are located within the folded domains. The cell bodies of both pigmented & no-pigmented neurons (arrows) as well as axons (arrowheads) contain LRRK2, seen only using antibodies against sites outside the folded domains (Ab1, E & Ab4, H). In contrast, Ab4 staining was much less intense in control tissue (L). The muscle layer of both large & small vessels was consistently found to contain high levels of LRRK2 in almost all PD cases (seen in E, G, & H) & strikingly the vessels are the only structure immunolabeled with Ab3 recognizing LRRK21838–2133 in all cases studied (G & K). Ab2 to LRRK21246–1265 did not recognize LBs, cell bodies or vessels in any case (B, F, & J). Scale bars: A-D & inset = 10 μm; E-L = 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416205168.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in PD. Four antibodies raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD (A-H) & age-matched controls (I-L). Intense immunolabeling of brainstem LBs in cases of PD was seen with Ab1 against LRRK2900–100 (A) & Ab4 against LRRK22500–2527(D). Both rim (A & D) & core (inset in D) of LBs were recognized. In contrast, LBs were not labelled in any case using antibodies directed against LRRK21246–1265 (Ab2, B) or LRRK21838–2133 (Ab3, C), for which the antigenic sites are located within the folded domains. The cell bodies of both pigmented & no-pigmented neurons (arrows) as well as axons (arrowheads) contain LRRK2, seen only using antibodies against sites outside the folded domains (Ab1, E & Ab4, H). In contrast, Ab4 staining was much less intense in control tissue (L). The muscle layer of both large & small vessels was consistently found to contain high levels of LRRK2 in almost all PD cases (seen in E, G, & H) & strikingly the vessels are the only structure immunolabeled with Ab3 recognizing LRRK21838–2133 in all cases studied (G & K). Ab2 to LRRK21246–1265 did not recognize LBs, cell bodies or vessels in any case (B, F, & J). Scale bars: A-D & inset = 10 μm; E-L = 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416205158.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416205187.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621239.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621810.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 kinase inhibition blocks Tat-induced S935 phosphorylation & inflammatory cytokine expression in BV-2 cells. (A) Western blot depicting pS935-LRRK2 & total LRRK2 protein levels 12 hours after saline or Tat-treatment ± LRRK2 kinase inhibition (LRRK2i). (B) Tat treatment significantly increased pS935-LRRK2, which was attenuated by LRRK2i. (C) We measured TNF-alpha , IL-6, MCP-1 & IL-10 mRNA levels by qRT-PCR 12 hours post saline or Tat treatment ± LRRK2i. LRRK2i attenuated Tat-induced TNF-alpha , IL-6, MCP-1 & IL-10 expression for all groups (*P <0.05, ***P <0.001, one way ANOVA, Newman-Keuls post-test). ANOVA, analysis of variance; LRRK2, leucine-rich repeat kinase2; pS935, phosphorylation of serine 935; Tat, trans activator of transcription. Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-261), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416212357.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in PD. Four antibodies raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD (A-H) & age-matched controls (I-L). Intense immunolabeling of brainstem LBs in cases of PD was seen with Ab1 against LRRK2900–100 (A) & Ab4 against LRRK22500–2527(D). Both rim (A & D) & core (inset in D) of LBs were recognized. In contrast, LBs were not labelled in any case using antibodies directed against LRRK21246–1265 (Ab2, B) or LRRK21838–2133 (Ab3, C), for which the antigenic sites are located within the folded domains. The cell bodies of both pigmented & no-pigmented neurons (arrows) as well as axons (arrowheads) contain LRRK2, seen only using antibodies against sites outside the folded domains (Ab1, E & Ab4, H). In contrast, Ab4 staining was much less intense in control tissue (L). The muscle layer of both large & small vessels was consistently found to contain high levels of LRRK2 in almost all PD cases (seen in E, G, & H) & strikingly the vessels are the only structure immunolabeled with Ab3 recognizing LRRK21838–2133 in all cases studied (G & K). Ab2 to LRRK21246–1265 did not recognize LBs, cell bodies or vessels in any case (B, F, & J). Scale bars: A-D & inset = 10 μm; E-L = 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621837.jpg)
![Flow Cytometry: LRRK2 Antibody - BSA Free [NB300-268] - Inhibition of LRRK2 kinase activity attenuates Mn-induced apoptosis.(A) After pre-treatment with GSK (1 μM) for 90 min, cells (HMC3) were exposed to Mn (250 μM) for the designated time periods, followed by annexin V & PI staining & flow cytometry analysis to determine apoptosis. Early & late apoptotic cells (Q2 & Q3) were analyzed. (B,C) After pre-treatment with GSK (1 μM) for 90 min, cells (LRRK2 WT RAW 264.7 & HMC3) were exposed to Mn for designated time periods, followed by the MTT assay to determine cell viability, as described in the Methods section, (@@@, p < 0.001; *, p < 0.05; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3, apoptosis assay; n = 6, MTT assay). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621844.jpg)
![Western Blot: beta-III Tubulin Antibody [NB100-1612] - The levels of glial fibrillary acidic protein (GFAP) and S100beta as astrocytic protein marker proteins in the hippocampal area. Western blot images using GFAP, tubulin beta-3, and beta-actin antibodies to total protein lysate in hippocampal area. The statistical results of internal standardized GFAP/beta-tubulin ratio by beta-actin levels relative to young adult wild-type C57BL/6J. White and black bars indicate the wild-type C57BL/6J and Tet-mev-1 mice, respectively. Data are expressed as mean +/- SD; *P 12 in each group. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/acel.12523), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/beta-III-Tubulin-Antibody-Western-Blot-NB100-1612-img0006.jpg "Western Blot: beta-III Tubulin Antibody [NB100-1612] - The levels of glial fibrillary acidic protein (GFAP) and S100beta as astrocytic protein marker proteins in the hippocampal area. Western blot images using GFAP, tubulin beta-3, and beta-actin antibodies to total protein lysate in hippocampal area. The statistical results of internal standardized GFAP/beta-tubulin ratio by beta-actin levels relative to young adult wild-type C57BL/6J. White and black bars indicate the wild-type C57BL/6J and Tet-mev-1 mice, respectively. Data are expressed as mean +/- SD; *P 12 in each group. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/acel.12523), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: beta-III Tubulin Antibody [NB100-1612] - Beta-III Tubulin in rat primary motor neurons. Ab dilution 1:1000 in PBST (0.1% Triton X-100) + 10% GS O/N at 4C. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/beta-III-Tubulin-Antibody-Immunocytochemistry-Immunofluorescence-NB100-1612-img0011.jpg)
![Western Blot: beta-III Tubulin Antibody [NB100-1612] - The levels of glial fibrillary acidic protein (GFAP) and S100beta as astrocytic protein marker proteins in the hippocampal area. Western blot images using S100beta, tubulin beta-3, and beta-actin antibodies to total protein lysate in hippocampal area. The statistical results of internal standardized S100beta/beta-tubulin ratio by beta-actin levels relative to young adult wild-type C57BL/6J. White and black bars indicate the wild-type C57BL/6J and Tet-mev-1 mice, respectively. Data are expressed as mean +/- SD; *P 12 in each group. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/acel.12523), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/beta-III-Tubulin-Antibody-Western-Blot-NB100-1612-img0007.jpg)
![Western Blot: beta-III Tubulin Antibody [NB100-1612] - The levels of glial fibrillary acidic protein (GFAP) & S100 beta as astrocytic protein marker proteins in the hippocampal area. (A) Western blot images using GFAP, tubulin beta‐3, & beta ‐actin antibodies to total protein lysate in hippocampal area. The statistical results of internal standardized GFAP/ beta ‐tubulin ratio by beta ‐actin levels relative to young adult wild‐type C57BL/6J. White & black bars indicate the wild‐type C57BL/6J & Tet‐mev‐1 mice, respectively. Data are expressed as mean ± SD; *P 12 in each group. (B) Western blot images using S100 beta , tubulin beta‐3, & beta ‐actin antibodies to total protein lysate in hippocampal area. The statistical results of internal standardized S100 beta / beta ‐tubulin ratio by beta ‐actin levels relative to young adult wild‐type C57BL/6J. White & black bars indicate the wild‐type C57BL/6J & Tet‐mev‐1 mice, respectively. Data are expressed as mean ± SD; *P 12 in each group. (C) Micrographs of immunohistochemical analysis on paraffined hippocampal tissue sections using GFAP & S100 beta antibody. Brown cells indicate GFAP‐stained astrocytes. Scale bar = 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623715), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1612_chicken-polyclonal-beta-iii-tubulin-antibody-310202415533839.jpg)
![Immunohistochemistry Free-Floating: GFAP Antibody [NBP1-05198] - Staining of a section of mouse hippocampus stained with chicken pAb to GFAP, NBP1-05198, dilution 1:5000 in green and costained with rabbit pAb to FOX3/NeuN, dilution 1:5000, in red. The blue is DAPI staining of nuclear DNA. Following transcardial perfusion with 4% paraformaldehyde, mouse brain was post fixed for 24 hours, cut to 45 uM, and free-floating sections were stained with the above antibodies. The GFAP antibody stains a network of astroglial cells while the Fox3/NeuN antibody stains the nuclei and proximal perikarya of neurons.](http://images.novusbio.com/fullsize/GFAP-Antibody-NBP1-05198-img0001.jpg "Immunohistochemistry Free-Floating: GFAP Antibody [NBP1-05198] - Staining of a section of mouse hippocampus stained with chicken pAb to GFAP, NBP1-05198, dilution 1:5000 in green and costained with rabbit pAb to FOX3/NeuN, dilution 1:5000, in red. The blue is DAPI staining of nuclear DNA. Following transcardial perfusion with 4% paraformaldehyde, mouse brain was post fixed for 24 hours, cut to 45 uM, and free-floating sections were stained with the above antibodies. The GFAP antibody stains a network of astroglial cells while the Fox3/NeuN antibody stains the nuclei and proximal perikarya of neurons.")
![Western Blot: GFAP Antibody [NBP1-05198] - Analysis of whole brain lysates using chicken pAb to GFAP, NBP1-05198, dilution 1:5000 in green: [1] protein standard (red), [2] rat brain, [3] mouse brain. The strong band at about 50 kDa corresponds to the GFAP protein. Smaller proteolytic fragments and alternate transcripts of GFAP may also be detected on such blots.](http://images.novusbio.com/fullsize/GFAP-Antibody-NBP1-05198-img0002.jpg)
![Immunohistochemistry-Paraffin: RBFOX3/NeuN Antibody [NBP1-77686] - IHC analysis of formalin fixed paraffin embedded tissue section from hippocampus of mouse brain with NeuN antibody at 1:200 dilution. The antibody generated a strong nuclear with weak cytoplasmic staining in NeuN reactive cells.](http://images.novusbio.com/fullsize/RBFOX3-NeuN-Antibody-Immunohistochemistry-Paraffin-NBP1-77686-img0007.jpg "Immunohistochemistry-Paraffin: RBFOX3/NeuN Antibody [NBP1-77686] - IHC analysis of formalin fixed paraffin embedded tissue section from hippocampus of mouse brain with NeuN antibody at 1:200 dilution. The antibody generated a strong nuclear with weak cytoplasmic staining in NeuN reactive cells.")
![Immunohistochemistry-Paraffin: RBFOX3/NeuN Antibody [NBP1-77686] - JAK3 colocalized with neurons labeled with NeuN. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fneur.2017.00363/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RBFOX3-NeuN-Antibody-Immunohistochemistry-Paraffin-NBP1-77686-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: RBFOX3/NeuN Antibody [NBP1-77686] - Neuro2a cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-RBFOX3/NeuN Antibody NBP1-77686 at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/RBFOX3-NeuN-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-77686-img0013.jpg)
![Western Blot: RBFOX3/NeuN Antibody [NBP1-77686] - Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/RBFOX3-NeuN-Antibody-Western-Blot-NBP1-77686-img0012.jpg)
![Flow Cytometry: RBFOX3/NeuN Antibody [NBP1-77686] - An intracellular stain was performed on Hek293 cells with NBP1-77686AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/RBFOX3-NeuN-Antibody-Flow-Cytometry-NBP1-77686-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: RBFOX3/NeuN Antibody [NBP1-77686] - NeuN antibody was tested in U2OS cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/RBFOX3-NeuN-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-77686-img0005.jpg)
![Immunohistochemistry: RBFOX3/NeuN Antibody [NBP1-77686] - Analysis of NeuN in mouse brain using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/RBFOX3-NeuN-Antibody-Immunohistochemistry-NBP1-77686-img0008.jpg)
![Flow Cytometry: RBFOX3/NeuN Antibody [NBP1-77686] - An intracellular stain was performed on U2OS cells with RBFOX3/NeuN Antibody NBP1-77686AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/RBFOX3-NeuN-Antibody-Flow-Cytometry-NBP1-77686-img0009.jpg)
![Immunocytochemistry/ Immunofluorescence: RBFOX3/NeuN Antibody - BSA Free [NBP1-77686] - Double immunofluorescence indicates that NF-kappa B & CCL5 were co-localized with microglia, astrocytes, & neurons in the ipsilateral L4–5 spinal cord on day 7 after CCI.NF-kappa B (green) colocalizes with Iba-1, GFAP, & NeuN (red) in laminae II–III of the superficial dorsal horn (A). CCL5 (red) co-localizes with Iba-1, GFAP, & NeuN (green) in the medial superficial dorsal horn (laminae II–III) (B). NF-kappa B (green) co-localizes with CCL5 (red) in laminae II–IV of the superficial dorsal horn following CCI on day 7 in the sham & CCI groups in the ipsilateral L4–5 spinal cord (C). Two single stained images (yellow) were merged. Scale = 100 μm. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115120), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77686_rabbit-polyclonal-rbfox3-neun-antibody-31020241538241.jpg)
![Immunocytochemistry/ Immunofluorescence: RBFOX3/NeuN Antibody - BSA Free [NBP1-77686] - (A) Representative Western blots depicting phosphorylated JAK3 (pJAK3), total JAK3, & corresponding beta -actin levels in the ipsilateral (CXI) versus the contralateral (CXC) cortex at 24 h in sham & mice subjected to permanent middle cerebral artery occlusion (pMCAO). (B,C) Quantified pJAK3 & JAK3 values normalized to beta -actin in the cortex of sham & mice subjected to stroke. Both pJAK3 & JAK3 are significantly increased in the ipsilateral cortex of stroked animals (*P < 0.05 & **P < 0.01 with respect to sham ipsilateral/contralateral & stroke contralateral; sham, n = 5; stroke, n = 13). Data were analyzed using a two-way ANOVA (ipsilateral/contralateral or sham/stroke) with Bonferroni post-test. (D) Diagram showing peri-infarct brain region from which images were taken (n = 3). Scale bar is 10 µm, & magnification is 60×. (E) JAK3 colocalized with microglia/macrophages labeled with Iba-1. (F) JAK3 colocalized with neurons labeled with NeuN. (G) JAK3 colocalized with endothelial cells labeled with CD31. (H) JAK3 is not colocalized with astrocytes labeled with GFAP. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28790974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77686_rabbit-polyclonal-rbfox3-neun-antibody-310202416175267.jpg)
![Immunohistochemistry-Paraffin: SOX2 Antibody [NB110-37235] - Staining of human uterus, endometrial glands.](http://images.novusbio.com/fullsize/SOX2-Antibody-Immunohistochemistry-Paraffin-NB110-37235-img0012.jpg)
![Western Blot: SOX2 Antibody [NB110-37235] - Detection of SOX2 in mouse brain lysate using NB110-37235 at 0.5 ug/mL.](http://images.novusbio.com/fullsize/SOX2-Antibody-Western-Blot-NB110-37235-img0008.jpg)
![Flow Cytometry: SOX2 Antibody [NB110-37235] - An intracellular stain was performed on A549 with NB110-37235 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylgiht 550.](http://images.novusbio.com/fullsize/SOX2-Antibody-Flow-Cytometry-NB110-37235-img0015.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: SOX2 Antibody [NB110-37235] - MDA-MB-231 subclones transfected with NTC or HIF-1 alpha shRNA vector were treated with vehicle (V) or paclitaxel (P) and immunoblot assay was performed. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/SOX2-Antibody-Western-Blot-NB110-37235-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: SOX2 Antibody - BSA Free [NB110-37235] - Rat FR cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with SOX2 Antibody (NB110-37235) at 2ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/SOX2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-37235-img0019.jpg)
![Flow Cytometry: SOX2 Antibody - BSA Free [NB110-37235] - An intracellular stain was performed on U-251 MG cells with SOX2 Antibody NB110-37235 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/SOX2-Antibody---BSA-Free-Flow-Cytometry-NB110-37235-img0020.jpg)
![Western Blot: SOX2 Antibody [NB110-37235] - Expression of pluripotency factor Sox2 in human head and neck cancer cell lines FaDu and HN5. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/SOX2-Antibody-Western-Blot-NB110-37235-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: SOX2 Antibody [NB110-37235] - Staining of SOX2 in NTERA2 cells with Dylight 488 (Green). Alpha-tubulin and nuclei were counterstained with Dylight 550 (Red) and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/SOX2-Antibody-Immunocytochemistry-Immunofluorescence-NB110-37235-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: SOX2 Antibody [NB110-37235] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-SOX2 (NB110-37235) at a 1:200 dilution overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with and anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/SOX2-Antibody-Immunocytochemistry-Immunofluorescence-NB110-37235-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: SOX2 Antibody - BSA Free [NB110-37235] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with SOX2 Antibody (NB110-37235) at 2ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/SOX2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-37235-img0018.jpg)
![Western Blot: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of 25 ug of mouse brain (lane 1) and rat brain (lane 2) cell lysates.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Western-Blot-NB300-556-img0020.jpg "Western Blot: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of 25 ug of mouse brain (lane 1) and rat brain (lane 2) cell lysates.")
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Control immunolocalization of plasma membrane AMPA receptor subunits (external epitopes) in hippocampal neuronal cultures. H) Immunolabeling of non-permeabilized neuronal cultures with ani-GluA1 (green). (I) Immunolabeling with the postsynaptic marker anti-PSD95 [66] after permeabilization of neuronal cultures. (J) Merging of (H) and (I) showing postsynaptic labeling of GluA1. Scale bar (valid for all images): 10 um. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0140868), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0025.jpg)
![Immunohistochemistry-Paraffin: PSD-95 Antibody (6G6-1C9) [NB300-556] - Confocal images of dissociated hippocampal cultures. Double labeling with anti-syntaxin-1 Double labeling with antibodies against syntaxin-1 (D) and synaptophysin (E) indicates that syntaxin-1 is colocalized with presynaptic marker (F). Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/Article/10.3389/fnmol.2016.00010/abstract), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunohistochemistry-Paraffin-NB300-556-img0024.jpg)
![Flow Cytometry: PSD-95 Antibody (6G6-1C9) [NB300-556] - An intracellular stain was performed on HeLa cells with PSD-95 Antibody (6G6-1C9) NB300-556AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Flow-Cytometry-NB300-556-img0023.jpg)
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 using PSD95 Monoclonal antibody (6G6-1C9) shows staining in HeLa cells. PSD95 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing PSD95 at a dilution of 1:100-1:200 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 using PSD95 Monoclonal antibody (6G6-1C9) shows staining in U251 glioma cells. PSD95 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing PSD95 at a dilution of 1:100-1:200 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 using PSD95 Monoclonal antibody (6G6-1C9) shows staining in C6 glioma cells. PSD95 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing PSD95 at a dilution of 1:100-1:200 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of Post Synaptic Density 95kD protein (PSD95, green) in cultured primary cortical neurons. Primary cortical neurons are isolated and cultured using the Primary Neuron Isolation Kit. At day 28, neurons were fixed with 4% paraformaldehyde, permeablilized with 0.1% triton X-100 in HBSS for 10 minutes at room temperature, and blocked with 3% BSA in PBS for 30 minutes at room temperature. Cells were probed with a PSD95 monoclonal antibody at a dilution of 1:500 for 2 hours at room temperature or overnight at 4C, washed with HBSS, and incubated with DyLight 488 goat anti-mouse IgG secondary antibody at dilution of 1:500 for 1 hour at room temperature.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0019.jpg)
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Mixed 3 week old rat cortical cultures (21 DIV) were labelled with anti-PSD95 (1:650) and visualised with anti-mouse Alexa647 (1:2000). The antibody labels small punctae along neuronal processes as expected. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0021.jpg)
![Flow Cytometry: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 in Neuro-2a cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Flow-Cytometry-NB300-556-img0012.jpg)
![Flow Cytometry: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 in SH-SY5Y cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Flow-Cytometry-NB300-556-img0013.jpg)
![Flow Cytometry: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 in U87-MG cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Flow-Cytometry-NB300-556-img0014.jpg)
![Immunocytochemistry/ Immunofluorescence: PSD-95 Antibody (6G6-1C9) - BSA Free [NB300-556] - Confocal images of dissociated hippocampal cultures. Double labeling with anti-syntaxin-1 (A) & anti-Tuj1 (B) demonstrates that syntaxin-1 is located along the dendrites & gives characteristic punctate labeling (C). Double labeling with antibodies against syntaxin-1 (D) & synaptophysin (E) indicates that syntaxin-1 is colocalized with presynaptic marker (F). Double labeling for syntaxin-1 (G) & PSD-95 (H) shows partial colocalization postsynaptic (I). Scale bars: 10 μm. (J–L) Western blot analysis of synaptosomes (Syn), synaptic cytosolic fraction (Cy), active zone (AZ) & post synaptic density (PSD). Labeled with anti-synaptophysin (J) anti-PSD95 (K) & anti-syntaxin-1 (L). Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/Article/10.3389/fnmol.2016.00010/abstract), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-556_mouse-monoclonal-psd-95-antibody-6g6-1c9-310202415392516.jpg)
![Western Blot: PSD-95 Antibody (6G6-1C9) - BSA Free [NB300-556] - Confocal images of dissociated hippocampal cultures. Double labeling with anti-syntaxin-1 (A) & anti-Tuj1 (B) demonstrates that syntaxin-1 is located along the dendrites & gives characteristic punctate labeling (C). Double labeling with antibodies against syntaxin-1 (D) & synaptophysin (E) indicates that syntaxin-1 is colocalized with presynaptic marker (F). Double labeling for syntaxin-1 (G) & PSD-95 (H) shows partial colocalization postsynaptic (I). Scale bars: 10 μm. (J–L) Western blot analysis of synaptosomes (Syn), synaptic cytosolic fraction (Cy), active zone (AZ) & post synaptic density (PSD). Labeled with anti-synaptophysin (J) anti-PSD95 (K) & anti-syntaxin-1 (L). Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/Article/10.3389/fnmol.2016.00010/abstract), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-556_mouse-monoclonal-psd-95-antibody-6g6-1c9-310202415334924.jpg)
![Immunocytochemistry/ Immunofluorescence: PSD-95 Antibody (6G6-1C9) - BSA Free [NB300-556] - Confocal images of dissociated hippocampal cultures.Double labeling with anti-TUJ1 (A) & anti-VAMP2 (B) demonstrates that VAMP2 is located along the dendrites & gives characteristic punctate labeling (C). Double labeling with antibodies against synaptophysin (P38) (D) & VAMP2 (E) indicates that VAMP2 is colocalized with the presynaptic marker (F). Double labeling for PSD-95 (G) & VAMP2 (H) shows partial colocalization postsynaptic (I). Small, high-resolution pictures of single synapses from (F) & (I) are shown in the right part of these images, respectively. Scale bar: 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26488171), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-556_mouse-monoclonal-psd-95-antibody-6g6-1c9-310202415395948.jpg)
![Immunocytochemistry/ Immunofluorescence: PSD-95 Antibody (6G6-1C9) - BSA Free [NB300-556] - Control immunolocalization of plasma membrane AMPA receptor subunits (external epitopes) in hippocampal neuronal cultures.(A) Beta-tubulin (green, anti-TuJ1) labeling of dendrite, after anti-GluA1 external epitope [66] labeling & subsequent plasma membrane permeabilization. Note punctate GluA1 [66] labeling along the dendrite. (B) Synaptophysin (P38, green) & GluA1 [66]. (C) Synaptophysin (green) & GluA2 [66]. (D) Labeling with anti-GluA1. (E) Labeling with anti-GluA1, but the antibody was preincubated with the peptide antigen before staining. (F) Labeling with anti-GluA2. (G) Labeling with anti-GluA2, but the antibody was preincubated with the peptide antigen before staining. (H) Immunolabeling of non-permeabilized neuronal cultures with ani-GluA1 (green). (I) Immunolabeling with the postsynaptic marker anti-PSD95 [66] after permeabilization of neuronal cultures. (J) Merging of (H) & (I) showing postsynaptic labeling of GluA1. Scale bar (in A, valid for all images): 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26488171), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-556_mouse-monoclonal-psd-95-antibody-6g6-1c9-310202416205115.jpg)
![Immunohistochemistry-Paraffin: Ki67/MKI67 Antibody (8D5) [NBP2-22112] - Analysis of paraffin-embedded lung cancer (left) and rectal cancer (right) using Ki67 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/Ki-67-MKI67-Antibody-8D5-Immunohistochemistry-Paraffin-NBP2-22112-img0002.jpg "Immunohistochemistry-Paraffin: Ki67/MKI67 Antibody (8D5) [NBP2-22112] - Analysis of paraffin-embedded lung cancer (left) and rectal cancer (right) using Ki67 mouse mAb with DAB staining.")
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (8D5) [NBP2-22112] - A549 human alveolar adenocarcinoma cell line, fixation with PFA 4%, blocking (PBS, 1% BSA, 0.1% Tween), primary antibody: 1:100 in blocking buffer, O/N. Secondary antibody: AlexaFluor 594, 1 hour, RT. Counterstained with DAPI. Imaged with a fluorescence microscope. This image was submitted via customer review.](http://images.novusbio.com/fullsize/Ki-67-MKI67-Antibody-8D5-Immunocytochemistry-Immunofluorescence-NBP2-22112-img0006.jpg)
![<b>Genetic Strategies Validation. </b>Simple Western: Ki67/MKI67 Antibody (8D5) [NBP2-22112] - Detection of Ki67/MKI67 by Simple WesternTM. Simple Western lane view shows lysates of HeLa parental cell line and Ki67 knockout (KO) HeLa cell line. A specific band was detected for Ki67/MKI67 at approximately 317 kDa (as indicated) in the parental cell line, but is not detectable in the knockout HeLa cell line using 1:100 of Mouse Anti-Ki67/MKI67 Monoclonal Antibody (Catalog # NBP2-22112). GAPDH is shown as a loading control. This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-8D5-Knockout-Validated-NBP2-22112-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (8D5) [NBP2-22112] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP2-22112 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-8D5-Immunocytochemistry-Immunofluorescence-NBP2-22112-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (8D5) [NBP2-22112] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP2-22112 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-8D5-Immunocytochemistry-Immunofluorescence-NBP2-22112-img0007.jpg)
![Western Blot: Ki67/MKI67 Antibody (8D5) [NBP2-22112] - Analysis using Ki67 mouse mAb against Hela (1), MCF-7 (2) and Raji (3) cell lysate.](http://images.novusbio.com/fullsize/Ki-67-MKI67-Antibody-8D5-Western-Blot-NBP2-22112-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (8D5) [NBP2-22112] - U-251 MG cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-Ki67/MKI67 Antibody [8D5] conjugated to FITC (NBP2-22112F) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-8D5-Immunocytochemistry-Immunofluorescence-NBP2-22112-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (8D5) [NBP2-22112] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-Ki-67 (8D5) conjugated to Alexa Fluor 488 [NBP2-22112AF488] at 10ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Ki-67-MKI67-Antibody-8D5-Immunocytochemistry-Immunofluorescence-NBP2-22112-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (8D5) [NBP2-22112] - Ki67 antibody was tested at 1:100 in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red). Image objective 40x.](http://images.novusbio.com/fullsize/Ki-67-MKI67-Antibody-8D5-Immunocytochemistry-Immunofluorescence-NBP2-22112-img0004.jpg)
![Western Blot: alpha Tubulin Antibody (YOL1/34) [NB100-1639] - Total protein from human HeLa and A431, mouse 3T3 and rat PC12 cell lines was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-alpha Tubulin in block buffer and detected with an anti-mouse HRP secondary antibody using West Pico PLUS chemiluminescence detection reagent. Alpha tubulin molecular weight: 50 kDa.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YOL1-34-Western-Blot-NB100-1639-img0008.jpg "Western Blot: alpha Tubulin Antibody (YOL1/34) [NB100-1639] - Total protein from human HeLa and A431, mouse 3T3 and rat PC12 cell lines was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-alpha Tubulin in block buffer and detected with an anti-mouse HRP secondary antibody using West Pico PLUS chemiluminescence detection reagent. Alpha tubulin molecular weight: 50 kDa.")
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YOL1/34) - BSA Free [NB100-1639] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with alpha Tubulin Antibody [YOL1/34] (NB100-1639) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YOL1-34-BSA-Free-Immunocytochemistry-Immunofluorescence-NB100-1639-img0014.jpg)
![Flow (Intracellular): alpha Tubulin Antibody (YOL1/34) [NB100-1639] - An intracellular stain was performed on HeLa cells with Tubulin [YOL1/34] Antibody NB100-1639 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rat IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 488.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YOL1-34-Flow-Intracellular-NB100-1639-img0007.jpg)
![Flow Cytometry: alpha Tubulin Antibody (YOL1/34) [NB100-1639] - An intracellular stain was performed on HeLa cells with alpha Tubulin Antibody [YOL1/34] NB100-1639AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647. Image using the Alexa Fluor 647 format of this antibody.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YOL1-34-Flow-Cytometry-NB100-1639-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YOL1/34) [NB100-1639] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-Tubulin Antibody [YOL1/34] at 5 ug/ml overnight at 4C and detected with an anti-rat Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YOL1-34-Immunocytochemistry-Immunofluorescence-NB100-1639-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YOL1/34) - BSA Free [NB100-1639] - alpha Tubulin Antibody (YOL1/34) [NB100-1639] - NIH3T3 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-Tubulin Antibody [YOL1/34] at 5 ug/ml overnight at 4C and detected with an anti-rat Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YOL1-34-Immunocytochemistry-Immunofluorescence-NB100-1639-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YOL1/34) [NB100-1639] - PC12 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-Tubulin Antibody [YOL1/34] at 5 ug/ml overnight at 4C and detected with an anti-rat Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YOL1-34-Immunocytochemistry-Immunofluorescence-NB100-1639-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: alpha Tubulin Antibody (YOL1/34) [NB100-1639] - Mutants unable to ubiquitinate histone H2B-K123 display growth and Cdc14 release defects when combined with MEN mutants. Representative images from Cdc14 release assay. Cells are assayed for spindle morphology and Cdc14 release phenotype by indirect immunofluorescence with anti-tubulin or anti-HA, which recognizes the HA-tagged version of Cdc14 in all strains. Cells are visualized by nuclear staining with DAPI and by differential interference contrast (DIC) optics for comparison. No release refers to dense nucleolar staining of Cdc14-HA, full release refers to cells with uniform Cdc14-HA localization throughout the nucleus, while partial release refers to cells with both nuclear and residual nucleolar staining. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pgen.1000588), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/alpha-Tubulin-Antibody-YOL1-34-Immunocytochemistry-Immunofluorescence-NB100-1639-img0012.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further and promoted activation of astrocytes and microglia, and enhanced the p38/JNK pathway to aggravate the release of IL-1beta and TNF-alpha in the SDH of CYP-induced cystitis. Western blots showing the expression of BDNF was further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean +/- SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group.](http://images.novusbio.com/fullsize/BDNF-Antibody-Western-Blot-NB100-98682-img0010.jpg "<b>Biological Strategies Validation. </b>Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further and promoted activation of astrocytes and microglia, and enhanced the p38/JNK pathway to aggravate the release of IL-1beta and TNF-alpha in the SDH of CYP-induced cystitis. Western blots showing the expression of BDNF was further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean +/- SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry: BDNF Antibody [NB100-98682] - Effects of mBMSC and EA treatment on the expression of mBDNF and NT4 in neurons. Photomicrographs for mBDNF/NeuN or NT4/NeuN double-positive cells in the striatum and hippocampus (n = 5). The number of mBDNF/NeuN double-positive cells in the SVZ + striatum and hippocampus was significantly higher in the EA-treated MCAO group and the combined mBMSC + EA-treated MCAO group, compared to the number in the other groups. The number of NT4/NeuN double-positive cells in the hippocampus was significantly higher in the EA-treated MCAO group than in the vehicle-treated MCAO group. #p < 0.05 and ##p < 0.01 versus control group; *p < 0.05, **p < 0.01, and ***p < 0.001 versus vehicle-treated MCAO group; &&p < 0.01 versus mBMSC-treated MCAO group. Scale bar = 100 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-018-20481-3) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-NB100-98682-img0007.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Human platelet lysate and recombinant mature BDNF. Blocking: 1% LFDM for 30 min at RT; primary antibody (1:1000) incubated at 4C overnight.](http://images.novusbio.com/fullsize/BDNF-Antibody-Western-Blot-NB100-98682-img0006.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0001.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0003.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0005.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Effect of treatment with FX extract on CREB/BDNF signaling. (a-c) Differences in the phosphorylation of CREB & expression of BDNF between groups in the PFC & hippocampus (n = 3-4). (d, e) pCREB & BDNF immunofluorescence was assessed in the PFC & hippocampus (n = 3-4). Mean ± SD. #P < 0.05 versus normal group; ∗P < 0.05 & ∗∗P < 0.01 versus control group. Scale bar = 200 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30065945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415371951.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Effect of treatment with FX extract on CREB/BDNF signaling. (a-c) Differences in the phosphorylation of CREB & expression of BDNF between groups in the PFC & hippocampus (n = 3-4). (d, e) pCREB & BDNF immunofluorescence was assessed in the PFC & hippocampus (n = 3-4). Mean ± SD. #P < 0.05 versus normal group; ∗P < 0.05 & ∗∗P < 0.01 versus control group. Scale bar = 200 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30065945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415175223.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Antagonized TrkB could restrain the activation of astrocytes & microglia & supress the p38/JNK pathway to alleviate the release of IL-1 beta & TNF-alpha in the SDH of CYP-induced cystitis. Western blots showed that the overexpression of a BDNF, b TrkB, cp-TrkB, d Iba1, e GFAP, fp-p38, gp-JNK, h TNF-alpha , & i IL-1 beta were downregulated in comparison to the CYP + DMSO group after ANA-12 treatment. All data were calculated as mean ± SEM (n = 5 per group). **p < 0.01, ***p < 0.001 vs. control group. ##p < 0.01, ###p < 0.001 vs. CYP + ANA-12 group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415291934.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further & promoted activation of astrocytes & microglia, & enhanced the p38/JNK pathway to aggravate the release of IL-1 beta & TNF-alpha in the SDH of CYP-induced cystitis. a BDNF treated every other day after CYP injection could further lower the mechanical withdrawal threshold & suppress the retrieval of mechanical threshold when compared with the CYP + PBS group. After the exogenous BDNF injection, Western blots showing the expression of b BDNF, c TrkB, dp-TrkB, e Iba1, f GFAP, gp-p38, hp-JNK, i TNF-alpha , & j IL-1 beta were all further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284921.jpg)
![Immunohistochemistry: BDNF Antibody [NB100-98682] - Effects of mBMSC & EA treatment on the expression of trophic factors. (A) Photomicrographs & (B‒D) histograms for mBDNF, NT4, & VEGF expression (n = 4–5). mBDNF expression was markedly increased by treatment with mBMSC and/or EA compared to vehicle treatment. mBDNF expression levels were higher in the EA-treated MCAO group than in the mBMSC-treated MCAO group. NT4 expression in the SVZ & hippocampus was significantly higher in the combined mBMSC & EA treatment group than in the other groups. VEGF expression in the hippocampus was markedly higher in the mBMSC treatment group than in the vehicle-treated MCAO group. #p < 0.05, ##p < 0.01, & ###p < 0.001 versus control group; *p < 0.05, **p < 0.01, & ***p < 0.001 versus vehicle-treated MCAO group; &p < 0.05, &&p < 0.01, & &&&p < 0.001 versus mBMSC-treated MCAO group; Scale bar = 1 mm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29391466), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284912.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - The expression of BDNF-TrkB signaling in the SDH of CYP-induced cystitis. a Changes of the mechanical threshold in CYP-induced cystitis model. Compared to that in the control group, the mechanical threshold of the cystitis group decreased significantly after the CYP injection & remained low until day 17, & the minimum threshold value was reached on day 12. The expression of b BDNF, c TrkB, & dp-TrkB were evaluated by western blots. Compared to the control group, they were upregulated on days 8, 12, & 17. e Immunofluorescence double staining assay of BDNF & p-TrkB in the SDH. BDNF & p-TrkB (red), NeuN, GFAP, & OX-42( green), co-localization (yellow). BDNF was mainly colocalized in neurons which mainly located in Laminate II to IV. & TrkB receptors expressed in neurons, microglia, & astrocytes. The white dotted lines in picture “BDNF/NeuN” showed the laminate of the SDH according to Rexed & Steiner. Scale bar = 100 μm. All data were calculated as mean ± SEM (n = 5 per group). *p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284910.jpg)